Diagnosis and prediction of CKD progression by assessment of urinary peptides

Journal of the American Society of Nephrology

Volumn 26, Issue 8, 2015, Pages 1999-2010

  Schanstra, Joost P ^a,b   Zürbig, Petra ^c   Alkhalaf, Alaa ^d   Argiles, Angel ^e   Bakker, Stephan J L ^d   Beige, Joachim ^f   Bilo, Henk J G ^d,g   Chatzikyrkou, Christos ^h   Dakna, Mohammed ^c   Dawson, Jesse ⁱ   Delles, Christian ⁱ   Haller, Hermann ^j   Haubitz, Marion ^k   Husi, Holger ⁱ   Jankowski, Joachim ^l,m   Jerums, George ⁿ   Kleefstra, Nanne ^d,g   Kuznetsova, Tatiana ^o,p   Maahs, David M ^q   Menne, Jan ^j   Mullen, William ⁱ   Ortiz, Alberto ^r   Persson, Frederik ^s   Rossing, Peter ^s,t,u   Ruggenenti, Piero ^v   Rychlik, Ivan ^w   Serra, Andreas L ^x   Siwy, Justyna ^c,m   Snell Bergeon, Janet ^w   Spasovski, Goce ^y   Staessen, Jan A ^p   Vlahou, Antonia ^t,z   Mischak, Harald ^c,i   Vanholder, Raymond ^aa,ab   more..

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RD Nephrologie   (France)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g ISALA HOSPITAL   (Netherlands)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k KLINIKUM FULDA   (Germany)

^l UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o UNIVERSITY OF LEUVEN   (Belgium)

^p UNIVERSITY OF LEUVEN   (Belgium)

^q UNIVERSITY OF COLORADO DENVER   (United States)

^r AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^s STENO DIABETES CENTER   (Denmark)

^t AARHUS UNIVERSITY   (Denmark)

^u UNIVERSITY OF COPENHAGEN   (Denmark)

^v MARIO NEGRI INST PHARMACOL RES   (Italy)

^w CHARLES UNIVERSITY   (Czech Republic)

^x UNIVERSITY OF ZURICH   (Switzerland)

^y SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^z Academy of Athens Biomedical Research Foundation   (Greece)

^aa UNIVERSITY OF PLYMOUTH   (United Kingdom)

^ab GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA 1 ANTITRYPSIN; ALPHA1 BETA GLYCOPROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; BETA 2 MICROGLOBULIN; CALGRANULIN B; CD99 ANTIGEN; CLUSTERIN; COLLAGEN; COLLAGEN ALPHA 1 CHAIN; CREATININE; FIBRINOGEN; FIBRINOGEN ALPHA CHAIN; GLYCOPROTEIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN CHAIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; OSTEOPONTIN; PEPTIDE; PLASMINOGEN; PREALBUMIN; PROTEOME; SERUM ALBUMIN; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG; URINARY PEPTIDE; BIOLOGICAL MARKER;

ADULT; ALBUMINURIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GLOMERULAR FILTRATION BARRIER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TISSUE REPAIR; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; GLOMERULUS FILTRATION RATE; URINE;

ADULT; AGED; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926612422     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014050423     Document Type: Article

References (53)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: Global dimension and perspectives. Lancet 382: 260-272, 2013
2. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, Walter LC, Mehta KM, Steinman MA, Allon M, McClellan WM, Landefeld CS: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18: 2758-2765, 2007
3. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlisterF, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006
4. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72: 247-259, 2007
5. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005
6. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, Lieske JC, Seccombe DW, Jones G, Bunk DM, Curhan GC, Narva AS; National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in Urine: Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 55: 24-38, 2009
7. Rossing P: Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49: 11-19, 2006
8. MacIsaac RJ, Ekinci EI, Jerums G: 'Progressive diabetic nephropathy. How useful is microalbuminuria?: Contra'. Kidney Int 86: 50-57, 2014
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
10. Matheson A, Willcox MD, Flanagan J, Walsh BJ: Urinary biomarkers involved in type 2 diabetes: A review. Diabetes Metab Res Rev 26: 150-171, 2010
11. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ: New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 82[Suppl 1]: S30-S37, 2008
12. Steinke JM: The natural progression of kidney injury in young type 1 diabetic patients. Curr Diab Rep 9: 473-479, 2009
13. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF: Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom Rev 28: 703-724, 2009
14. Mischak H, Schanstra J P: CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 5: 9-23, 2011
15. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P; PREDICTIONS Network: Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 19: 1283-1290, 2008
16. Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P: Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437, 2010
17. Alkhalaf A, Zürbig P, Bakker SJ, Bilo HJ, Cerna M, Fischer C, Fuchs S, Janssen B, Medek K, Mischak H, Roob JM, Rossing K, Rossing P, Rychlík I, Sourij H, Tiran B, Winklhofer-Roob BM, Navis GJ; PREDICTIONS Group: Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 5: e13421, 2010
18. Molin L, Seraglia R, Lapolla A, Ragazzi E, Gonzalez J, Vlahou A, Schanstra JP, Albalat A, Dakna M, Siwy J, Jankowski J, Bitsika V, Mischak H, Zürbig P, Traldi P: A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J Proteomics 75: 5888-5897, 2012
19. Roscioni SS, de Zeeuw D, Hellemons ME, Mischak H, Zürbig P, Bakker SJ, Gansevoort RT, Reinhard H, Persson F, Lajer M, Rossing P, Lambers Heerspink HJ: A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56: 259-267, 2013
20. Zürbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P: Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61: 3304-3313, 2012
21. Chou KM, Lee CC, Chen CH, Sun CY: Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS ONE 8: e54863, 2013
22. Spasovski G, Ortiz A, Vanholder R, El Nahas M: Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. Proteomics Clin Appl 5: 233-240, 2011
23. Taal MW, Brenner BM: Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int 70: 1694-1705, 2006
24. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 49: 1399-1408, 2000
25. Macisaac RJ, Jerums G: Diabetic kidney disease with and without al-buminuria. Curr Opin Nephrol Hypertens 20: 246-257, 2011
26. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS: In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77: 57-64, 2010
27. Liu KD, Yang W, Anderson AH, Feldman HI, Demirjian S, Hamano T, He J, Lash J, Lustigova E, Rosas SE, Simonson MS, Tao K, Hsu CY; Chronic Renal Insufficiency Cohort (CRIC) study investigators: Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 83: 909-914, 2013
28. Argilés Á, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H: CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE 8: e62837, 2013
29. Suh JH, Miner JH: The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol 9: 470-477, 2013
30. Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM: The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2: 997-1007, 2008
31. Murri M, Insenser M, Bernal-Lopez MR, Perez-Martinez P, Escobar-Morreale HF, Tinahones FJ: Proteomic analysis of visceral adipose tissue in pre-obese patients with type 2 diabetes. Mol Cell Endocrinol 376: 99-106, 2013
32. Awartani F: Serum immunoglobulin levels in type 2 diabetes patients with chronic periodontitis. J Contemp Dent Pract 11: 001-008, 2010
33. Bellei E, Rossi E, Lucchi L, Uggeri S, Albertazzi A, Tomasi A, Iannone A: Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. Proteomics Clin Appl 2: 478-491, 2008
34. Caseiro A, Ferreira R, Padrão A, Quintaneiro C, Pereira A, Marinheiro R, Vitorino R, Amado F: Salivary proteome and peptidome profiling in type 1 diabetes mellitus using aquantitative approach. J Proteome Res 12: 1700-1709, 2013
35. Shamsara J, Behravan J, Falsoleiman H, Mohammadpour AH, Rendeirs J, Ramezani M: Pentoxifylline administration changes protein expression profile of coronary artery disease patients. Gene 487: 107-111, 2011
36. Navarro JF, Mora C, Muros M, García J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol 16: 2119-2126, 2005
37. Jung GS, Kim MK, Jung YA, Kim HS, Park IS, Min BH, Lee KU, Kim JG, Park KG, Lee IK: Clusterin attenuates the development of renal fibrosis. J Am Soc Nephrol 23: 73-85, 2012
38. Chen K, Li Y, Dai Y, Li J, Qin Y, Zhu Y, Zeng T, Ban X, Fu L, Guan XY: Characterization of tumor suppressive function of cornulin in esopha-geal squamous cell carcinoma. PLoS ONE 8: e68838, 2013
39. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543, 2010
40. Marek CJ, Wallace K, Durward E, Koruth M, Leel V, Leiper LJ, Wright MC: Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics. Comp Hepatol 8: 1, 2009
41. Facio FN Jr, Sena AA, Araújo LP, Mendes GE, Castro I, Luz MA, Yu L, Oliani SM, Burdmann EA: Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med (Berl) 89: 51-63, 2011
42. Choi YH, McNally BT, Igarashi P: Zyxin regulates migration of renal epithelial cells throughactivationofhepatocytenuclear factor-1b. Am J Physiol Renal Physiol 305: F100-F110, 2013
43. Decramer S, Parant O, Beaufils S, Clauin S, Guillou C, Kessler S, Aziza J, Bandin F, Schanstra JP, Bellanné-Chantelot C: Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol 18: 923-933, 2007
44. Faguer S, Mayeur N, Casemayou A, Pageaud AL, Courtellemont C, Cartery C, Fournie GJ, Schanstra JP, Tack I, Bascands JL, Chauveau D: Hnf-1b transcription factor is an early hif-1a-independent marker of epithelial hypoxia and controls renal repair. PLoS ONE 8: e63585, 2013
45. Levin A, Stevens PE: Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85: 49-61, 2014
46. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
47. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, Levin A: Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 382: 158-169, 2013
48. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, Dakna M, Coon JJ, Mischak H: Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplas-mic antibody-associated vasculitis. Mol Cell Proteomics 8: 2296-2307, 2009
49. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF: Discovery and validation of new protein bio-markers for urothelial cancer: A prospective analysis. Lancet Oncol 7: f230-240, 2006
50. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, Sundmacher A, Schlegelberger B, Kolch W, Mischak H: Mass spectrometry for the detection of differentially expressed proteins: A comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 18: 149-156, 2004
51. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, Mischak H, Metzger J: Quantitative urinary proteome analysis for biomarkerevaluation in chronic kidneydisease. J Proteome Res 8: 268-281, 2009
52. DeLeo JM: Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. In: Proceedings of the Second International Symposium on Uncertainty Modeling and Analysis, College Park, MD, IEEE, 1993, pp 318-325
53. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172, discussion 207-212, 2008